Collaboration and Strategic Alliances (Details) - USD ($) |
1 Months Ended | |||
|---|---|---|---|---|
Apr. 30, 2025 |
Oct. 31, 2024 |
Mar. 31, 2025 |
Dec. 31, 2024 |
|
| Accounts receivable, net | $ 47,447,000 | $ 3,473,000 | ||
| Deferred revenue | 45,000,000 | $ 0 | ||
| Viatris Inc. | License | ||||
| Proceeds from collaborators | $ 25,000,000 | |||
| Novo Nordisk | License | ||||
| Revenue, Remaining Performance Obligation, Amount | 45 | |||
| Accounts receivable, net | 45 | |||
| Deferred revenue | $ 45 | |||
| Novo Nordisk | License | Subsequent Event | ||||
| Proceeds from collaborators | $ 45,000,000 | |||
| Variable consideration, regulatory milestones | 485,000,000 | |||
| Variable consideration, sales milestones | $ 475,000,000 | |||